Business Description
Solvonis Therapeutics PLC
ISIN : GB00BMD1Z199
Share Class Description:
STU:J4I: Ordinary ShareTotal Employee Number:
6Description
Solvonis Therapeutics PLC focuses on the development of therapeutic solutions. The company is engaged in the development of novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders focusing on addiction and psychiatry. The products in company's pipeline include SVN-001, SVN-002, SVN-015. SVN-114, and others.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 22.93 | |||||
Equity-to-Asset | 0.82 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 65.8 | |||||
3-Year EPS without NRI Growth Rate | 66.2 | |||||
3-Year FCF Growth Rate | 67.8 | |||||
3-Year Book Growth Rate | -71.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 39.96 | |||||
9-Day RSI | 41.93 | |||||
14-Day RSI | 42.32 | |||||
3-1 Month Momentum % | -50 | |||||
6-1 Month Momentum % | -40 | |||||
12-1 Month Momentum % | -25 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4 | |||||
Quick Ratio | 4 | |||||
Cash Ratio | 3.58 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -302.9 | |||||
Shareholder Yield % | -35.28 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -106.23 | |||||
ROA % | -84.69 | |||||
ROIC % | -67.22 | |||||
3-Year ROIIC % | -33.36 | |||||
ROCE % | -95.12 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.7 | |||||
EV-to-EBIT | -1.67 | |||||
EV-to-EBITDA | -1.67 | |||||
EV-to-FCF | -3.03 | |||||
Price-to-GF-Value | 0.05 | |||||
Earnings Yield (Greenblatt) % | -59.85 | |||||
FCF Yield % | -29.15 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Solvonis Therapeutics PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.002 | ||
| Beta | 0.3344 | ||
| 3-Year Sharpe Ratio | 0.28 | ||
| 3-Year Sortino Ratio | 0.9 | ||
| Volatility % | 222.47 | ||
| 14-Day RSI | 42.32 | ||
| 14-Day ATR (€) | 0.000721 | ||
| 20-Day SMA (€) | 0.00125 | ||
| 12-1 Month Momentum % | -25 | ||
| 52-Week Range (€) | 0.001 - 0.0065 | ||
| Shares Outstanding (Mil) | 6,806.4 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Solvonis Therapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Solvonis Therapeutics PLC Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-09-30 | In 70 days | ||
| General meeting for 2026 | 2026-06-19 08:00 | 0.00 (+0.00%) | ||
| Annual report for 2025 | 2026-04-29 | 0.00 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-04-29 | 0.00 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-09-30 | 0.01 (+0.00%) | ||
| General meeting for 2025 | 2025-06-27 12:00 | 0.00 (+0.00%) | ||
| Annual report for 2024 | 2025-04-16 | 0.00 (+0.00%) | ||
| Fourth quarter earnings results for 2024 | 2025-04-16 | 0.00 (+0.00%) | ||
| Third quarter earnings results for 2024 | 2025-02-24 | 0.00 (+0.00%) | ||
| Second quarter earnings results for 2024 | 2024-09-13 | 0.00 (+0.00%) |
Show
Entries
Solvonis Therapeutics PLC Frequently Asked Questions
What is Solvonis Therapeutics PLC(STU:J4I)'s stock price today?
The current price of STU:J4I is €0.00. The 52 week high of STU:J4I is €0.01 and 52 week low is €0.00.
When is next earnings date of Solvonis Therapeutics PLC(STU:J4I)?
The next earnings date of Solvonis Therapeutics PLC(STU:J4I) is 2026-09-30 Est..
Does Solvonis Therapeutics PLC(STU:J4I) pay dividends? If so, how much?
Solvonis Therapeutics PLC(STU:J4I) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Solvonis Therapeutics PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers